Victory Capital Management’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-39,204
| Closed | -$3.33M | – | 2617 |
|
|
2020
Q3 | $3.33M | Sell |
39,204
-777,090
| -95% | -$39.3M | ﹤0.01% | 1291 |
|
|
2020
Q2 | $28.9M | Sell |
816,294
-2,818,536
| -78% | -$82.4M | 0.04% | 634 |
|
|
2020
Q1 | $49M | Buy |
3,634,830
+2,016,570
| +125% | +$33.9M | 0.04% | 573 |
|
|
2019
Q4 | $34.2M | Buy |
1,618,260
+1,588,944
| +5,420% | +$28M | 0.04% | 626 |
|
|
2019
Q3 | $389K | Buy |
+29,316
| New | +$431K | ﹤0.01% | 1982 |
|
|
2019
Q2 | – | Sell |
-2,130,280
| Closed | -$40.9M | – | 1875 |
|
|
2019
Q1 | $40.9M | Buy |
2,130,280
+350,520
| +20% | +$5.65M | 0.09% | 344 |
|
|
2018
Q4 | $25.4M | Sell |
1,779,760
-233,650
| -12% | -$4.64M | 0.06% | 475 |
|
|
2018
Q3 | $41.9M | Sell |
2,013,410
-58,750
| -3% | -$1.39M | 0.09% | 393 |
|
|
2018
Q2 | $49M | Buy |
2,072,160
+199,320
| +11% | +$4.01M | 0.1% | 313 |
|
|
2018
Q1 | $27.4M | Buy |
1,872,840
+762,648
| +69% | +$12.5M | 0.06% | 495 |
|
|
2017
Q4 | $17.9M | Buy |
+1,110,192
| New | +$13.1M | 0.04% | 603 |
|
Victory Capital Management's IMMU Position: Q4 2020 in Review
Victory Capital Management sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 39,204 shares — an estimated $3.33M sold.
Victory Capital Management first reported a position in IMMU in Q4 2017 and held it in 11 quarters. The position peaked at $49M in Q2 2018. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- Victory Capital Management reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- Victory Capital Management sold 39,204 Immunomedics Inc shares in Q4 2020, an estimated $3.33M.
- Victory Capital Management first reported a position in Immunomedics Inc in Q4 2017 and held it in 11 quarters.
- Victory Capital Management's Immunomedics Inc position peaked at $49M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on Victory Capital Management's 13F filing for Q4 2020, filed 1 Feb 2021.